OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody-Positive Individuals.
Alyssa Ylescupidez, Cate Speake, Susan L Pietropaolo, Darrell M Wilson, Andrea K Steck, Jennifer L Sherr, Jason L Gaglia, Christine Bender, Sandra Lord, Carla J Greenbaum
Author Information
Alyssa Ylescupidez: Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA. ORCID
Cate Speake: Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA. ORCID
Susan L Pietropaolo: Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Darrell M Wilson: Division of Pediatric Endocrinology, Stanford University School of Medicine, Palo Alto, CA 94304, USA.
Andrea K Steck: Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Jennifer L Sherr: Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT 06511, USA. ORCID
Jason L Gaglia: Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.
Christine Bender: Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA.
Sandra Lord: Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA. ORCID
Carla J Greenbaum: Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA.
CONTEXT: The value of continuous glucose monitoring (CGM) for monitoring autoantibody (AAB)-positive individuals in clinical trials for progression of type 1 diabetes (T1D) is unknown. OBJECTIVE: Compare CGM with oral glucose tolerance test (OGTT)-based metrics in prediction of T1D. METHODS: At academic centers, OGTT and CGM data from multiple-AAB relatives were evaluated for associations with T1D diagnosis. Participants were multiple-AAB-positive individuals in a TrialNet Pathway to Prevention (TN01) CGM ancillary study (n = 93). The intervention was CGM for 1 week at baseline, 6 months, and 12 months. Receiver operating characteristic (ROC) curves of CGM and OGTT metrics for prediction of T1D were analyzed. RESULTS: Five of 7 OGTT metrics and 29/48 CGM metrics but not HbA1c differed between those who subsequently did or did not develop T1D. ROC area under the curve (AUC) of individual CGM values ranged from 50% to 69% and increased when adjusted for age and AABs. However, the highest-ranking metrics were derived from OGTT: 4/7 with AUC ���80%. Compared with adjusted multivariable models using CGM data, OGTT-derived variables, Index60 and DPTRS (Diabetes Prevention Trial-Type 1 Risk Score), had higher discriminative ability (higher ROC AUC and positive predictive value with similar negative predictive value). CONCLUSION: Every 6-month CGM measures in multiple-AAB-positive individuals are predictive of subsequent T1D, but less so than OGTT-derived variables. CGM may have feasibility advantages and be useful in some settings. However, our data suggest there is insufficient evidence to replace OGTT measures with CGM in the context of clinical trials.
